摘要
目的探讨研究伊立替康联合阿帕替尼治疗晚期肺癌的疗效。方法选取2018年5月—2019年5月在医院确诊并接受治疗的晚期肺癌患者82例,按照随机数字表法的分配原则将其分为研究组和对照组两个组别,每组41例。其中,给予对照组患者使用阿帕替尼进行治疗,研究组患者在对照组患者的基础上联合使用伊立替康进行治疗,对比两组患者的临床疗效、生存质量以及不良反应发生情况。结果研究组患者的临床控制率显著高于对照组患者(P<0.05);研究组患者的生存质量的提高率明显高于对照组患者(P<0.05);研究组患者的不良反应发生率明显低于对照组患者(P<0.05)。结论在晚期肺癌患者的临床治疗过程中,联合使用伊立替康和阿帕替尼能够有效的改善患者的生存质量,提高对晚期肺癌的临床控制效果,并且在不良反应发生率方面大大减少。
Objective To investigate the efficacy of irinotecan combined with apatinib in the treatment of advanced lung cancer.Methods A total of 82 patients with advanced lung cancer diagnosed and treated in our hospital from May 2018 to May 2019 were selected and divided into study group and control group according to the distribution principle of random number table,41 cases in each group.Patients in the control group were treated with apatinib,and patients in the research group were treated with irinotecan on the basis of the control group.The clinical efficacy,quality of life and the incidence of adverse reactions in the two groups were compared.Results The clinical control rate in the study group was significantly higher than that in the control group(P<0.05).The improvement rate of quality of life in the study group was significantly higher than that in the control group(P<0.05).The incidence of ADR in study group was significantly lower than that in control group(P<0.05).Conclusion In the clinical treatment of patients with advanced lung cancer,the combined use of irinotecan and apatinib can effectively improve the quality of life of patients,improve the clinical control effect of advanced lung cancer,and greatly reduce the incidence of adverse reactions.
作者
何义
HE Yi(Department of Oncology,Songzi People's Hospital,Songzi Hubei 434200,China)
出处
《中国继续医学教育》
2021年第18期136-140,共5页
China Continuing Medical Education
关键词
伊立替康
阿帕替尼
晚期肺癌
临床疗效
生存质量
不良反应
irinotecan
apatinib
advanced lung cancer
clinical effect
quality of life
adverse reactions
